Nomura Holdings’s Acceleron Pharma XLRN Stock Holding History

Nomura Holdings’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-8,000	Closed	-$203K	–	2164
2015 Q3	$203K	Buy	+8,000	New	+$240K	﹤0.01%	1406

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Nomura Holdings's XLRN Position: Q2 2021 in Review

Nomura Holdings sold out of Acceleron Pharma (XLRN) in Q2 2021, closing a stake of 2,250 shares — an estimated $306K sold.

Nomura Holdings first reported a position in XLRN in Q1 2021 and held it in 1 quarter. The position peaked at $306K in Q1 2021. 271 funds tracked by Wall St. Rank hold XLRN as of Q2 2021.

Nomura Holdings reported no remaining Acceleron Pharma position as of Q2 2021 after selling out during the quarter.
Nomura Holdings sold 2,250 Acceleron Pharma shares in Q2 2021, an estimated $306K.
Nomura Holdings first reported a position in Acceleron Pharma in Q1 2021 and held it in 1 quarter.
Nomura Holdings's Acceleron Pharma position peaked at $306K in Q1 2021.
271 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2021.

Based on Nomura Holdings's 13F filing for Q2 2021, filed 16 Aug 2021.